Placebo + RG7314

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

Pre-clinical
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Autism Spectrum Disorder

Conditions

Autism Spectrum Disorder

Trial Timeline

Sep 1, 2013 → Sep 1, 2016

About Placebo + RG7314

Placebo + RG7314 is a phase 2 stage product being developed by Roche for Autism Spectrum Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01793441. Target conditions include Autism Spectrum Disorder.

What happened to similar drugs?

0 of 10 similar drugs in Autism Spectrum Disorder were approved

Approved (0) Terminated (2) Active (8)
🔄Cariprazine + PlaceboAbbViePhase 3
Balovaptan + PlaceboRochePhase 3
🔄Brexpiprazole + PlaceboLundbeckPhase 3
🔄BrexpiprazoleLundbeckPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01793441Phase 2Completed

Competing Products

20 competing products in Autism Spectrum Disorder

See all competitors